NASDAQ · Biotechnology · USD
XBiotech Inc. (XBIT) Stock Analysis
XBiotech Inc. (XBIT) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
XBIT Key Statistics
As of Oct 21, 2026Trading
- Open
- $2.04
- Previous Close
- $2.02
- Day's Range
- 1.98–2.04
- 52-Week Range
- 1.91–3.44
- Volume
- 58.25K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 0.80
Valuation
- Market Cap
- $60.67M
- P/E Ratio
- unprofitable
- Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
- 15.31
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −1.48
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$45.54M
- Shares Outstanding
- 30.49M
- 1-Year Return
- −23.17%
Dividend and dates
- Avg Volume
- 47.16K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, XBIT closed at $1.99, −23.17% over 1 year.
XBiotech Inc. (XBIT) has a market capitalization of $60.67M.
In fiscal 2025, XBIT reported revenue of $0.00.
XBIT Stock Return by Calendar Year
XBiotech Inc. (XBIT) 10-year return: what $10,000 became
- 1 year
- $10,000 $7,683
- −23.17%
- 5 years
- $10,000 $1,422
- −85.78%
- 10 years
- $10,000 $1,480
- −85.20%
If you had invested $10,000 in XBiotech Inc. (XBIT) 10 years ago, at the close on October 21, 2016, it would have been worth $1,480 at the close on October 21, 2026: −85.20% in total, −17.39% a year, with dividends reinvested. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −16.74% |
| 2025 | −39.49% |
| 2024 | −1.25% |
| 2023 | +13.96% |
| 2022 | −68.46% |
| 2021 | −17.46% |
| 2020 | −16.15% |
| 2019 | +267.42% |
| 2018 | +28.93% |
| 2017 | −61.07% |
| 2016 (partial year) | −35.54% |
As of October 21, 2026.
XBIT Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$45.54M | — |
| 2024 | $0.00 | −$38.53M | — |
| 2023 | $0.00 | −$24.56M | — |
| 2022 | $4.01M | −$32.90M | −820.4% |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$55.69M | −$45.54M | — |
| 2024 | $0.00 | — | −$42.47M | −$38.53M | — |
| 2023 | $0.00 | $0.00 | −$37.51M | −$24.56M | — |
| 2022 | $4.01M | $3.36M | −$34.49M | −$32.90M | −820.4% |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Recent News
XBiotech Announces Positive Phase II Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metastatic Colorectal Cancer
YahooXBiotech Announces Data From Its Phase II Portion Of Multicenter TASKIN Clinical Study Meets Pre-Specifed Primary Efficacy Success Criterion Under Simon Two-Stage Design; 61.3% Participants In Vilamakitug Experimental Arm Were Alive, Surpassing Threshold Of 42, More Surviving Patients
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B